Hayashi S, Mori I, Nonoyama T, Mitsumori K
Pharmacology Laboratories, Takeda Chemical Industries Ltd., Osaka, Japan.
Toxicol Pathol. 1998 Jul-Aug;26(4):556-61. doi: 10.1177/019262339802600412.
Spontaneous proliferative liver lesions were found in 15 (13 males and 2 females) of 244 (122 of each sex) transgenic (Tg) mice carrying the human prototype c-H-ras gene (rasH2). The liver lesions included 3 foci of cellular alteration, 1 hepatocellular adenoma, 5 hepatocellular carcinomas, and 4 hepatic hemangiosarcomas in the males and 1 focus of cellular alteration and 1 hepatocellular carcinoma in the females. The mutation patterns of the human and endogenous mouse c-H-ras codon 61 in these proliferative liver lesions were analyzed by DNA amplification using polymerase chain reaction, single-strand conformation polymorphism (PCR-SSCP), and oligonucleotide dot blot hybridization. The hepatocellular carcinomas in 4 males and 1 female contained a point mutation in the mouse c-H-ras gene: 3, 1, and 1 carcinomas had a CAA to AAA transversion at the first base of codon 61, a CAA to CTA transversions, and a CAA to CGA transition at the second base of codon 61, respectively. No point mutations in the human c-H-ras transgene were detected in any hepatocellular carcinoma. All 4 hepatic hemangiosarcomas had a CAG to CTG transversion at codon 61 of the human c-H-ras gene, but no point mutations were detected in codon 61 of the mouse c-H-ras gene. No mutations in human or mouse c-H-ras codon 61 were detected in altered cell foci or hepatocellular adenoma. These results indicate that spontaneous liver tumors in rasH2 Tg mice contain different mutation patterns depending on the histologic type or cell origin of the tumors (i.e., hepatocellular carcinomas or hepatic hemangiosacomas). The absence of similar mutations in foci of cellular alteration and the hepatocellular adenoma suggests that the occurrence of codon 61 point mutations is a late event in the progression of hepatocellular neoplasia in rasH2 Tg mice.
在携带人类原型c-H-ras基因(rasH2)的244只转基因(Tg)小鼠(雌雄各122只)中,有15只(13只雄性和2只雌性)出现了自发性增殖性肝损伤。肝损伤包括雄性小鼠的3个细胞改变灶、1个肝细胞腺瘤、5个肝细胞癌和4个肝血管肉瘤,以及雌性小鼠的1个细胞改变灶和1个肝细胞癌。通过聚合酶链反应(PCR)、单链构象多态性分析(PCR-SSCP)和寡核苷酸斑点印迹杂交技术对这些增殖性肝损伤中人类和内源性小鼠c-H-ras密码子61的突变模式进行了分析。4只雄性和1只雌性的肝细胞癌在小鼠c-H-ras基因中存在一个点突变:3只、1只和1只肝细胞癌分别在密码子61的第一个碱基处发生了CAA到AAA的颠换、CAA到CTA的颠换以及在密码子61的第二个碱基处发生了CAA到CGA的转换。在任何肝细胞癌中均未检测到人类c-H-ras转基因的点突变。所有4个肝血管肉瘤在人类c-H-ras基因密码子61处均发生了CAG到CTG的颠换,但在小鼠c-H-ras基因密码子61处未检测到点突变。在细胞改变灶或肝细胞腺瘤中未检测到人类或小鼠c-H-ras密码子61的突变。这些结果表明,rasH2 Tg小鼠中的自发性肝肿瘤根据肿瘤的组织学类型或细胞起源(即肝细胞癌或肝血管肉瘤)包含不同的突变模式。细胞改变灶和肝细胞腺瘤中不存在类似突变表明,密码子61点突变的发生是rasH2 Tg小鼠肝细胞肿瘤发生过程中的一个晚期事件。